Dr. Backes on Rationale for Lenvatinib and Weekly Paclitaxel in Endometrial Cancer
2 Views
administrator
07/17/23
Floor J. Backes, MD, discusses the rationale and results from a phase I study exploring lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.
Website: https://www.onclive.com
Twitter: https://twitter.com/OncLive
Facebook: https://www.facebook.com/OncLive/
LinkedIn: https://www.linkedin.com/company/onclive
-
Category
Show more
Facebook Comments
No comments found